Drug Patent Expirations in September 2014

Drug Patent Expirations for September 2014

Tradename Applicant Generic Name Patent Number Patent Expiration
COMBIVENT RESPIMAT Boehringer Ingelheim albuterol sulfate; ipratropium bromide 5,662,271 Sep 2, 2014
BONIVA Roche ibandronate sodium 5,662,918 Sep 2, 2014
HEPSERA Gilead adefovir dipivoxil 5,663,159 Sep 2, 2014
VIGAMOX Alcon Pharms Ltd moxifloxacin hydrochloride 5,607,942*PED Sep 4, 2014
MOXEZA Alcon Pharms Ltd moxifloxacin hydrochloride 5,607,942*PED Sep 4, 2014
ALINIA Romark nitazoxanide 6,020,353 Sep 8, 2014
ALINIA Romark nitazoxanide 5,578,621 Sep 8, 2014
PROTOPIC Astellas tacrolimus 5,665,727 Sep 9, 2014
RENVELA Genzyme sevelamer carbonate 5,667,775 Sep 16, 2014
RENAGEL Genzyme sevelamer hydrochloride 5,667,775 Sep 16, 2014
ALINIA Romark nitazoxanide 6,020,353 Sep 18, 2014
EXUBERA Pfizer insulin recombinant human 6,543,448 Sep 21, 2014
ATRALIN Dow Pharm tretinoin 5,670,547 Sep 23, 2014
NAROPIN Fresenius Kabi Usa ropivacaine hydrochloride 5,670,524 Sep 23, 2014
NEORAL Novartis cyclosporine 5,985,321 Sep 26, 2014
IONSYS Incline Therap fentanyl hydrochloride 7,027,859 Sep 26, 2014
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.

Subscribers have access to valuable datasets, including:

  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison.
Contact Us with any questions.

Comments are closed.